<?xml version="1.0" encoding="utf-8" ?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving
and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">

<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="other">

<front>


<article-meta>


<title-group>
<article-title>Manuscript 1</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">0000-0001-8050-6447</contrib-id>
<name>
<surname>Svendsen</surname>
<given-names>Andreas Ludvig Ohm</given-names>
</name>
<string-name>Andreas Ludvig Ohm Svendsen</string-name>

<email>alosvendsen@health.sdu.dk</email>
<role vocab="https://credit.niso.org" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="https://credit.niso.org" vocab-term="project
administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project
administration</role>
<role vocab="https://credit.niso.org" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="https://credit.niso.org" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<xref ref-type="aff" rid="aff-1">a</xref>
<xref ref-type="corresp" rid="cor-1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Stage</surname>
<given-names>Tore B.</given-names>
</name>
<string-name>Tore B. Stage</string-name>

<xref ref-type="corresp" rid="cor-2">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="aff-1">
<institution-wrap>
<institution>SDU</institution>
</institution-wrap>







</aff>
<author-notes>
<corresp id="cor-1">alosvendsen@health.sdu.dk</corresp>
<corresp id="cor-2"></corresp>
</author-notes>









<history></history>


<abstract>
<p>This is an abstract …</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>3D primary human hepatocytes</kwd>
<kwd>Inflammation</kwd>
<kwd>Drug metabolism</kwd>
</kwd-group>




</article-meta>

</front>

<body>
<sec id="introduction">
  <title>Introduction</title>
  <p>Inflammation is a complex biological response that is pivotal in
  various pathological conditions. These range from systemic
  inflammatory diseases, such as rheumatoid arthritis and sepsis, to
  lower-grade chronic inflammatory states such as type 2 diabetes
  mellitus. Given the prevalence of systemic inflammation, understanding
  its interaction with drug metabolism is of substantial clinical
  relevance.</p>
  <p>Drug-metabolizing enzymes and transporters (DMETs), predominantly
  found in hepatocytes within the liver, are central to the
  biotransformation of a wide variety of compounds. Inflammation has
  been shown to modulate the activity of these DMETs, a phenomenon that
  could potentially affect the pharmacokinetics of numerous medications.
  For individuals with altered inflammatory status—whether due to a
  chronic condition like diabetes or an acute event like sepsis—this
  modulation can have significant implications. It may necessitate
  adjustments in drug dosages to avoid adverse effects or therapeutic
  failure.</p>
  <p>Previous research has provided valuable insights into the effects
  of inflammation on DMETs, but a clear correlation between in vitro
  studies and clinical observations remains elusive. For instance
  Dunvald et al.
  (<xref alt="1" rid="ref-dunvald" ref-type="bibr">1</xref>) conducted a
  comprehensive review of the clinical and in vitro evidence on
  inflammation-mediated modulation of DMETs and the impact on drug
  metabolism in humans. They found that in vitro studies in primary
  human hepatocytes revealed strong evidence of downregulation of key
  cytochrome P450 (CYP) enzymes by inflammatory cytokines such as IL-6
  and IL-1β. However, these studies often employed supraphysiological
  cytokine doses, which may not accurately represent the inflammatory
  conditions observed in patients.</p>
  <p>Levels of IL-6 and IL-1B in healthy individuals are generally low,
  with reports in range of ~10pg/ml in adults for IL-6, and ~2.5 pg/ml
  IL-1B in adults
  (<xref alt="2" rid="ref-kim2011" ref-type="bibr">2</xref>–<xref alt="5" rid="ref-strand2020" ref-type="bibr">5</xref>).
  In contrast, cytokine levels may be considerably elevated with IL-6
  levels of ~140 pg/mL, and I<underline>L-1B levels of ~100
  pg/mL</underline>, among patients with rheumatoid arthritis or SLE
  (<xref alt="6" rid="ref-umare2014" ref-type="bibr">6</xref>) to more
  than 1 ng/mL of IL-6 for patients with acute inflammation caused by
  sepsis (<xref alt="7" rid="ref-franco2019" ref-type="bibr">7</xref>).
  These variations in cytokine levels, which span a wide range in
  different pathological states, highlight the complex and dynamic
  nature of inflammation and underscore the need for research that
  considers this variability when investigating the effects of
  inflammation on drug-metabolizing enzymes.</p>
  <p>Recently, 3D primary human hepatocytes (PHH) have challenged 2D PHH
  as a more physiologically relevant culture method of PHH. 3D culture
  leads to more stable cell cultures that retain their hepatic phenotype
  for extended periods of time
  (<xref alt="8" rid="ref-bell2016" ref-type="bibr">8</xref>).
  Consequently, this 3D PHH have been shown to predict CYP induction and
  hepatotoxicity more accurately than 2D PHH
  (<xref alt="9" rid="ref-bell2018" ref-type="bibr">9</xref>,<xref alt="10" rid="ref-järvinen2023" ref-type="bibr">10</xref>).
  Historically, 2D PHH have been utilized to study the effect of drugs
  and inflammation on hepatocyte/liver function. However, the inherent
  limitations of 2D cultures, primarily their inability to maintain the
  physiological phenotype and liver-specific functions of hepatocytes,
  have prompted a shift towards the 3D liver spheroid models. This model
  is increasingly recognized for their physiological relevance and
  stability, offering a more accurate representation of hepatic
  responses. The 3D liver spheroids preserve liver cell phenotypes and
  functions over extended periods, thereby enhancing the reliability of
  drug-induced liver injury predictions and disease mechanism
  investigations. This advancement positions 3D liver spheroids as
  potentially the new standard for in vitro hepatocyte studies, while
  still being suitable for a high throughput setting, and financially
  accessible as opposed to even more advanced liver models (ref for last
  part)
  (<xref alt="1" rid="ref-dunvald" ref-type="bibr">1</xref>,<xref alt="11" rid="ref-ingelman-sundberg" ref-type="bibr">11</xref>)
  . Another claim for the lack of correlation discussed in the review by
  AC et al. is that there might be methodological limitations to the
  widespread use of 2D models of PHHs
  (<xref alt="1" rid="ref-dunvald" ref-type="bibr">1</xref>).</p>
  <p>We aimed to utilize 3D primary human hepatocytes
  (<xref alt="8" rid="ref-bell2016" ref-type="bibr">8</xref>) to study
  the impact of physiologically relevant concentrations of cytokines on
  CYP expression and activity. This may help further our understanding
  of the impact of inflammation on clinical drug metabolism among
  patients with inflammation. This, in turn, may inform more precise and
  adaptive prescribing strategies for patients in various inflammatory
  states.</p>
</sec>
<sec id="methods">
  <title>Methods</title>
  <sec id="d-spheroid-culture-of-phhs">
    <title>3D spheroid culture of PHHs</title>
    <sec id="materials">
      <title>Materials</title>
      <p>All necessary components for cell culture, including the
      medium, supplements, and compounds, were acquired from Thermo
      Fisher Scientific, unless stated otherwise.</p>
    </sec>
    <sec id="cell-source-and-preparation">
      <title>Cell source and preparation</title>
      <p>Three lots of cryopreserved primary human hepatocytes,
      specifically Hu8345-A, Hu8373-A and Hu8381, were procured from
      Thermo Fisher Scientific (Waltham, MA). All necessary cell culture
      reagents were sourced from the same supplier. All PHHs were
      qualified for spheroid formation per the manufacturer.</p>
    </sec>
    <sec id="spheroid-formation-and-maintenance">
      <title>Spheroid formation and maintenance</title>
      <p>The spheroid culture followed an adapted protocol from a
      previous study
      (<xref alt="8" rid="ref-bell2016" ref-type="bibr">8</xref>). In
      short 1500 hepatocytes per well in ultra-low attachment 96-well
      plates. Following seeding, the plates were centrifuged for 2
      minutes at 200g. Subsequently, the plates were incubated at 37°C
      with 5% CO2.</p>
      <p>On day 0 cells were seeded in culture medium, totaling 100 μL
      per well, consisting of 5% fetal bovine serum, 1 μM dexamethasone,
      5 μg/mL human recombinant insulin, 100 U/mL penicillin, 100 μg/mL
      streptomycin, 2 mM L-glutamine, and 15 mM HEPES in Williams’ E
      medium.</p>
      <p>After spheroid formation the seeding medium was replaced with
      FBS free maintenance medium. This medium comprised 0.1 μM
      dexamethasone, 10 μg/mL human recombinant insulin, 5.5 μg/mL
      transferrin, 6.7 ng/mL selenium, 100 U/mL penicillin, 100 μg/mL
      streptomycin, and 2 mM L-glutamine in Williams’ E medium. This FBS
      washout with maintenance medium was done with a 70% medium change
      on days 5-7.
      <monospace>For donor 1 (Hu8345-A) the maintenance also contained 5.35 μg/mL linoleic acid, 1.25 mg/mL bovine serum albumin and 15 mM HEPES. These supplements are, however, no longer recommended by the manufacturer</monospace><xref ref-type="fn" rid="fn1">1</xref><monospace>.</monospace></p>
      <p>Detailed descriptions of the spheroid culture process, as well
      as donor information, are available in the supplementary materials
      (Table SX).</p>
    </sec>
  </sec>
  <sec id="treatments">
    <title>Treatments</title>
    <p>Treatment with proinflammatory cytokines commenced on day 8 post
    seeding. The spheroids were exposed to IL-6 and IL-1β at
    concentrations of 0.01, 0.1, 1, and 10 ng/ml, alongside a vehicle
    control (0.1% bovine serum albumin in PBS). The cytokine treatments
    and vehicle control were diluted 1:1000 in the culture medium before
    administration.Re-dosing was done every other day for long-term
    cultures.</p>
  </sec>
  <sec id="spheroid-viability-and-morphology">
    <title>Spheroid viability and morphology</title>
    <p>The viability of the spheroids was monitored by measuring their
    ATP content, using the luminiscence CellTiter-Glo 3D assay from
    Promega (Madison, WI). Quantification of ATP was done using an ATP
    (from Thermo Fisher Scientific) standard curve. Viability was
    assessed every 2-3 days throughout the experiments.</p>
    <p>In addition to viability testing, the morphology of the spheroids
    was monitored. Imaging was done every second or third day, aligning
    with the viability assays. The spheroids were imaged using a light
    microscope equipped with a 10X magnification lens and a digital
    camera from Motic (Hong Kong, China).</p>
  </sec>
  <sec id="rna-extraction-cdna-synthesis-and-qpcr">
    <title>RNA extraction, cDNA synthesis and qPCR</title>
    <p>RNA was extracted using the phenol-chloroform method, following
    the manufacturer’s protocol from Qiagen with minor modifications
    (<xref alt="12" rid="ref-toni2018" ref-type="bibr">12</xref>). Each
    spheroid pool was treated with 1 mL of Qiazol (Qiagen) reagent for
    lysis, followed by co-precipitation with 15 μg of RNA grade glycogen
    (Thermo Fisher Scientific). The RNA pellet underwent three washes
    with 75% ethanol. Post-wash, a combination of heating and
    evaporation techniques was applied to remove residual ethanol and to
    facilitate the solubilization of the RNA pellet in water.</p>
    <p>RNA integrity was assessed for a subset of
    samples<xref ref-type="fn" rid="fn2">2</xref> using the Agilent
    BioAnalyzer, yielding RNA Integrity Number (RIN) values from 7 to
    9.8. These values indicate high-quality RNA. Concentration of RNA
    were estimated utilizing the NanoDrop spectrophotometer.</p>
    <p>Approximately 500 ng of extracted RNA was used for cDNA
    synthesis. This process was performed using the High-Capacity cDNA
    Reverse Transcription Kit with RNase Inhibitor (Thermo Fisher
    Scientific).</p>
    <p>For qPCR, 10 ng of cDNA, based on the initial RNA concentration,
    was utilized for each reaction. The reactions were set up in a 10 μL
    volume containing TaqMan Universal Master Mix II and target-specific
    TaqMan assays (detailed in Supplementary Methods). The qPCR was run
    for 40 cycles, following the manufacturer’s guidelines (Thermo
    Fisher Scientific). The PCR plate sample maximization method was
    applied(<xref alt="13" rid="ref-derveaux2010" ref-type="bibr">13</xref>),
    and a stable reference gene as well as no template controls and no
    reverse transcriptase controls was included in each plate.</p>
    <p>In the analysis of mRNA expression, the relative quantity was
    calculated by first determining the delta Cq ((C_q)) for each
    sample. This was achieved by subtracting the mean Cq of the control
    group from the mean Cq of the replicates of each sample. The
    relative quantity was then computed using the formula (2^{C_q}). For
    normalization, the relative quantity of the target gene in each
    sample was divided by the relative quantity of the reference gene
    (GAPDH or TBP). The average normalized expression for each
    biological group was subsequently calculated.</p>
  </sec>
  <sec id="activity">
    <title>Activity</title>
    <p>To assess the activity of CYP3A4 (maybe otheres also), an
    experiment was conducted using midazolam as a substrate in spheroids
    derived from donors 2 and 3, evaluated on day 12. Midazolam (Toronto
    Research Chemicals, Toronto, ON, Canada), was prepared as a 6,000×
    stock solution in DMSO. The final DMSO concentration in the enzyme
    activity assays was maintained at 0.15%. Prior to the introduction
    of midazolam to the spheroids, the cells underwent three washes with
    100 μL of maintenance medium. Between washes, the residual volume
    was kept at 20 μL, and before the final wash, the spheroids were
    incubated for 2 hours in a cell culture incubator.</p>
    <p>The concentration of midazolam in the assay was set at 10 μM,
    with a total volume of 100 μL per well. For the analysis, triplicate
    samples, each comprising a <strike>spheroid</strike> and medium from
    a single well, were collected at 0.5 (8 hours for other enzymes)
    hours post midazolam treatment. These samples were then stored at
    -80°C until further analysis. The specific methods used for the
    metabolite analysis of these samples are detailed in the
    supplementary material.</p>
  </sec>
  <sec id="quantitative-analysis-of-proteins-via-lc-ms-with-selective-immunoprecipitation">
    <title>Quantitative analysis of proteins via LC-MS with selective
    immunoprecipitation</title>
    <p>The quantification of human CYP <strike>and transporter</strike>
    proteins was performed using a targeted liquid chromatography-mass
    spectrometry approach, incorporating selective immunoprecipitation
    of peptides, as previously
    described(<xref alt="14" rid="ref-weiß2018" ref-type="bibr">14</xref>).
    Uniform numbers of spheroids were employed in each analysis for
    consistency. In summary, spheroids were lysed in a buffer of 42 mM
    ammonium bicarbonate, containing 1.14 mM dithiothreitol and 9 mM
    iodoacetamide, and incubated for 15 minutes at 90°C, a method
    adapted from Savaryn et al.
    (<xref alt="15" rid="ref-savaryn2020" ref-type="bibr">15</xref>).
    The lysates were then digested with MS-grade Pierce Trypsin Protease
    (Thermo Fisher Scientific) for 16 hours at 37°C. To halt the
    digestion, phenylmethanesulfonyl fluoride was added to each sample,
    achieving a final concentration of 1 mM and a total volume of 70 μL.
    A portion of the digested sample (25 μL) was then used for the
    immunoprecipitation of surrogate and internal standard peptides
    using triple X proteomics
    antibodies(<xref alt="14" rid="ref-weiß2018" ref-type="bibr">14</xref>).
    These peptides were subsequently analyzed and quantified through
    LC-MS. The specific surrogate peptides employed for protein
    quantification and the LC-gradients are detailed in the
    supplementary material. For data processing, Skyline software
    (MACOSS Lab, University of Washington, Seattle, WA) and TraceFinder
    4.1 (Thermo Fisher Scientific) were utilized.</p>
  </sec>
</sec>
<sec id="results">
  <title>Results</title>
  <sec id="viability-and-morphology">
    <title>Viability and morphology</title>
    <p>Mean relative viability is seen in
    <xref alt="Figure 1" rid="fig-viability-relative-overall">Figure 1</xref>.</p>
    <fig id="fig-viability-relative-overall">
      <caption><p>Figure 1: Note that the concentration of ATP of donor
      one on day 5 was to high. Data for this donor/day not
      trustworthy/viability to high. This yields a steep fall from day 5
      to 7</p></caption>
      <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-viability-Viability-fig-viability-relative-overall-output-1.png" />
    </fig>
    <p>The individual viability for each donor is seen in
    <xref alt="Figure 2" rid="fig-donor-viabilities">Figure 2</xref>.
    This fig is inserted as an image.</p>
    <fig id="fig-donor-viabilities">
      <caption><p>Figure 2</p></caption>
      <graphic id="fig-donor-viabilities" mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-viability-Viability-fig-donor-viabilities-output-2.png" />
    </fig>
    <p>Absolute overall viability is seen in
    <xref alt="Figure 3" rid="fig-viability-absolute-overall">Figure 3</xref></p>
    <fig id="fig-viability-absolute-overall">
      <caption><p>Figure 3: Note that the concentration of ATP of donor
      one on day 5 was to high. Data for this donor/day not
      trustworthy/viability to high</p></caption>
      <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-viability-Viability-fig-viability-absolute-overall-output-1.png" />
    </fig>
    <p>Morphology of the spheroids over time is seen in
    <xref alt="Figure 4" rid="fig-morph">Figure 4</xref></p>
    <fig id="fig-morph">
      <caption><p>Figure 4</p></caption>
      <graphic id="fig-morph" mimetype="image" mime-subtype="png" xlink:href="images/morphology_AS0006.png" />
    </fig>
  </sec>
  <sec id="mrna">
    <title>mRNA</title>
  </sec>
  <sec id="activity-1">
    <title>Activity</title>
  </sec>
</sec>
<sec id="references">
  <title>References</title>
</sec>
<sec id="supplementary-material">
  <title>Supplementary material</title>
</sec>
</body>

<back>
<ref-list>
  <title>Thesis abstract</title>
  <ref id="ref-dunvald">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Dunvald</surname><given-names>Ann-Cathrine Dalgård</given-names></name>
        <name><surname>Järvinen</surname><given-names>Erkka</given-names></name>
        <name><surname>Mortensen</surname><given-names>Christina</given-names></name>
        <name><surname>Stage</surname><given-names>Tore B.</given-names></name>
      </person-group>
      <article-title>Clinical and Molecular Perspectives on Inflammation-Mediated Regulation of Drug Metabolism and Transport</article-title>
      <source>Clinical Pharmacology &amp; Therapeutics</source>
      <volume>n/a</volume>
      <issue>n/a</issue>
      <uri>https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2432</uri>
      <pub-id pub-id-type="doi">10.1002/cpt.2432</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-kim2011">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Kim</surname><given-names>Hyun Ok</given-names></name>
        <name><surname>Kim</surname><given-names>Han-Soo</given-names></name>
        <name><surname>Youn</surname><given-names>Jong-Chan</given-names></name>
        <name><surname>Shin</surname><given-names>Eui-Cheol</given-names></name>
        <name><surname>Park</surname><given-names>Sungha</given-names></name>
      </person-group>
      <article-title>Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays</article-title>
      <source>Journal of Translational Medicine</source>
      <year iso-8601-date="2011-07-20">2011</year><month>07</month><day>20</day>
      <volume>9</volume>
      <issue>1</issue>
      <uri>https://doi.org/10.1186/1479-5876-9-113</uri>
      <pub-id pub-id-type="doi">10.1186/1479-5876-9-113</pub-id>
      <fpage>113</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-kleiner2013">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Kleiner</surname><given-names>Giulio</given-names></name>
        <name><surname>Marcuzzi</surname><given-names>Annalisa</given-names></name>
        <name><surname>Zanin</surname><given-names>Valentina</given-names></name>
        <name><surname>Monasta</surname><given-names>Lorenzo</given-names></name>
        <name><surname>Zauli</surname><given-names>Giorgio</given-names></name>
      </person-group>
      <article-title>Cytokine Levels in the Serum of Healthy Subjects</article-title>
      <source>Mediators of Inflammation</source>
      <year iso-8601-date="2013">2013</year>
      <volume>2013</volume>
      <uri>http://www.hindawi.com/journals/mi/2013/434010/</uri>
      <pub-id pub-id-type="doi">10.1155/2013/434010</pub-id>
      <fpage>1</fpage>
      <lpage>6</lpage>
    </element-citation>
  </ref>
  <ref id="ref-said2021">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Said</surname><given-names>Elias A.</given-names></name>
        <name><surname>Al-Reesi</surname><given-names>Iman</given-names></name>
        <name><surname>Al-Shizawi</surname><given-names>Nawal</given-names></name>
        <name><surname>Jaju</surname><given-names>Sanjay</given-names></name>
        <name><surname>Al-Balushi</surname><given-names>Mohammed S.</given-names></name>
        <name><surname>Koh</surname><given-names>Crystal Y.</given-names></name>
        <name><surname>Al-Jabri</surname><given-names>Ali A.</given-names></name>
        <name><surname>Jeyaseelan</surname><given-names>Lakshmanan</given-names></name>
      </person-group>
      <article-title>Defining IL-6 levels in healthy individuals: A meta-analysis</article-title>
      <source>Journal of Medical Virology</source>
      <year iso-8601-date="2021">2021</year>
      <volume>93</volume>
      <issue>6</issue>
      <uri>https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26654</uri>
      <pub-id pub-id-type="doi">10.1002/jmv.26654</pub-id>
      <fpage>3915</fpage>
      <lpage>3924</lpage>
    </element-citation>
  </ref>
  <ref id="ref-strand2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Strand</surname><given-names>Vibeke</given-names></name>
        <name><surname>Boklage</surname><given-names>Susan H.</given-names></name>
        <name><surname>Kimura</surname><given-names>Toshio</given-names></name>
        <name><surname>Joly</surname><given-names>Florence</given-names></name>
        <name><surname>Boyapati</surname><given-names>Anita</given-names></name>
        <name><surname>Msihid</surname><given-names>Jérôme</given-names></name>
      </person-group>
      <article-title>High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab</article-title>
      <source>Arthritis Research &amp; Therapy</source>
      <year iso-8601-date="2020-10-20">2020</year><month>10</month><day>20</day>
      <volume>22</volume>
      <issue>1</issue>
      <uri>https://doi.org/10.1186/s13075-020-02344-3</uri>
      <pub-id pub-id-type="doi">10.1186/s13075-020-02344-3</pub-id>
      <fpage>250</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-umare2014">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Umare</surname><given-names>Vinod</given-names></name>
        <name><surname>Pradhan</surname><given-names>Vandana</given-names></name>
        <name><surname>Nadkar</surname><given-names>Milind</given-names></name>
        <name><surname>Rajadhyaksha</surname><given-names>Anjali</given-names></name>
        <name><surname>Patwardhan</surname><given-names>Manisha</given-names></name>
        <name><surname>Ghosh</surname><given-names>Kanjaksha K.</given-names></name>
        <name><surname>Nadkarni</surname><given-names>Anita H.</given-names></name>
      </person-group>
      <article-title>Effect of Proinflammatory Cytokines (IL-6, TNF-α, and IL-1β) on Clinical Manifestations in Indian SLE Patients</article-title>
      <source>Mediators of Inflammation</source>
      <year iso-8601-date="2014-12-07">2014</year><month>12</month><day>07</day>
      <volume>2014</volume>
      <uri>https://www.hindawi.com/journals/mi/2014/385297/</uri>
      <pub-id pub-id-type="doi">10.1155/2014/385297</pub-id>
      <fpage>e385297</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-franco2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Franco</surname><given-names>Daniel Molano</given-names></name>
        <name><surname>Arevalo-Rodriguez</surname><given-names>Ingrid</given-names></name>
        <name><surname>Figuls</surname><given-names>Marta Roqué i</given-names></name>
        <name><surname>Oleas</surname><given-names>Nadia G. Montero</given-names></name>
        <name><surname>Nuvials</surname><given-names>Xavier</given-names></name>
        <name><surname>Zamora</surname><given-names>Javier</given-names></name>
      </person-group>
      <article-title>Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults</article-title>
      <source>Cochrane Database of Systematic Reviews</source>
      <year iso-8601-date="2019">2019</year>
      <issue>4</issue>
      <uri>https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011811.pub2/full</uri>
      <pub-id pub-id-type="doi">10.1002/14651858.CD011811.pub2</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-bell2016">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bell</surname><given-names>Catherine C.</given-names></name>
        <name><surname>Hendriks</surname><given-names>Delilah F. G.</given-names></name>
        <name><surname>Moro</surname><given-names>Sabrina M. L.</given-names></name>
        <name><surname>Ellis</surname><given-names>Ewa</given-names></name>
        <name><surname>Walsh</surname><given-names>Joanne</given-names></name>
        <name><surname>Renblom</surname><given-names>Anna</given-names></name>
        <name><surname>Fredriksson Puigvert</surname><given-names>Lisa</given-names></name>
        <name><surname>Dankers</surname><given-names>Anita C. A.</given-names></name>
        <name><surname>Jacobs</surname><given-names>Frank</given-names></name>
        <name><surname>Snoeys</surname><given-names>Jan</given-names></name>
        <name><surname>Sison-Young</surname><given-names>Rowena L.</given-names></name>
        <name><surname>Jenkins</surname><given-names>Rosalind E.</given-names></name>
        <name><surname>Nordling</surname><given-names>Åsa</given-names></name>
        <name><surname>Mkrtchian</surname><given-names>Souren</given-names></name>
        <name><surname>Park</surname><given-names>B. Kevin</given-names></name>
        <name><surname>Kitteringham</surname><given-names>Neil R.</given-names></name>
        <name><surname>Goldring</surname><given-names>Christopher E. P.</given-names></name>
        <name><surname>Lauschke</surname><given-names>Volker M.</given-names></name>
        <name><surname>Ingelman-Sundberg</surname><given-names>Magnus</given-names></name>
      </person-group>
      <article-title>Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease</article-title>
      <source>Scientific Reports</source>
      <year iso-8601-date="2016-05">2016</year><month>05</month>
      <volume>6</volume>
      <pub-id pub-id-type="doi">10.1038/srep25187</pub-id>
      <fpage>25187</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-bell2018">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bell</surname><given-names>Catherine C.</given-names></name>
        <name><surname>Dankers</surname><given-names>Anita C. A.</given-names></name>
        <name><surname>Lauschke</surname><given-names>Volker M.</given-names></name>
        <name><surname>Sison-Young</surname><given-names>Rowena</given-names></name>
        <name><surname>Jenkins</surname><given-names>Roz</given-names></name>
        <name><surname>Rowe</surname><given-names>Cliff</given-names></name>
        <name><surname>Goldring</surname><given-names>Chris E.</given-names></name>
        <name><surname>Park</surname><given-names>Kevin</given-names></name>
        <name><surname>Regan</surname><given-names>Sophie L.</given-names></name>
        <name><surname>Walker</surname><given-names>Tracy</given-names></name>
        <name><surname>Schofield</surname><given-names>Chris</given-names></name>
        <name><surname>Baze</surname><given-names>Audrey</given-names></name>
        <name><surname>Foster</surname><given-names>Alison J.</given-names></name>
        <name><surname>Williams</surname><given-names>Dominic P.</given-names></name>
        <name><surname>Ven</surname><given-names>Amy W. M. van de</given-names></name>
        <name><surname>Jacobs</surname><given-names>Frank</given-names></name>
        <name><surname>Houdt</surname><given-names>Jos van</given-names></name>
        <name><surname>Lähteenmäki</surname><given-names>Tuula</given-names></name>
        <name><surname>Snoeys</surname><given-names>Jan</given-names></name>
        <name><surname>Juhila</surname><given-names>Satu</given-names></name>
        <name><surname>Richert</surname><given-names>Lysiane</given-names></name>
        <name><surname>Ingelman-Sundberg</surname><given-names>Magnus</given-names></name>
      </person-group>
      <article-title>Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study</article-title>
      <source>Toxicological Sciences: An Official Journal of the Society of Toxicology</source>
      <year iso-8601-date="2018-04-01">2018</year><month>04</month><day>01</day>
      <volume>162</volume>
      <issue>2</issue>
      <pub-id pub-id-type="doi">10.1093/toxsci/kfx289</pub-id>
      <fpage>655</fpage>
      <lpage>666</lpage>
    </element-citation>
  </ref>
  <ref id="ref-järvinen2023">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Järvinen</surname><given-names>Erkka</given-names></name>
        <name><surname>Hammer</surname><given-names>Helen S.</given-names></name>
        <name><surname>Pötz</surname><given-names>Oliver</given-names></name>
        <name><surname>Ingelman-Sundberg</surname><given-names>Magnus</given-names></name>
        <name><surname>Stage</surname><given-names>Tore Bjerregaard</given-names></name>
      </person-group>
      <article-title>3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction</article-title>
      <source>Clinical Pharmacology &amp; Therapeutics</source>
      <year iso-8601-date="2023">2023</year>
      <volume>113</volume>
      <issue>6</issue>
      <uri>https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2887</uri>
      <pub-id pub-id-type="doi">10.1002/cpt.2887</pub-id>
      <fpage>1284</fpage>
      <lpage>1294</lpage>
    </element-citation>
  </ref>
  <ref id="ref-ingelman-sundberg">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Ingelman-Sundberg</surname><given-names>Magnus</given-names></name>
        <name><surname>Lauschke</surname><given-names>Volker M.</given-names></name>
      </person-group>
      <article-title>3D human liver spheroids for translational pharmacology and toxicology</article-title>
      <source>Basic &amp; Clinical Pharmacology &amp; Toxicology</source>
      <volume>n/a</volume>
      <issue>n/a</issue>
      <uri>https://onlinelibrary.wiley.com/doi/abs/10.1111/bcpt.13587</uri>
      <pub-id pub-id-type="doi">10.1111/bcpt.13587</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-toni2018">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Toni</surname><given-names>Lee S.</given-names></name>
        <name><surname>Garcia</surname><given-names>Anastacia M.</given-names></name>
        <name><surname>Jeffrey</surname><given-names>Danielle A.</given-names></name>
        <name><surname>Jiang</surname><given-names>Xuan</given-names></name>
        <name><surname>Stauffer</surname><given-names>Brian L.</given-names></name>
        <name><surname>Miyamoto</surname><given-names>Shelley D.</given-names></name>
        <name><surname>Sucharov</surname><given-names>Carmen C.</given-names></name>
      </person-group>
      <article-title>Optimization of phenol-chloroform RNA extraction</article-title>
      <source>MethodsX</source>
      <year iso-8601-date="2018-01-01">2018</year><month>01</month><day>01</day>
      <volume>5</volume>
      <uri>https://www.sciencedirect.com/science/article/pii/S2215016118300773</uri>
      <pub-id pub-id-type="doi">10.1016/j.mex.2018.05.011</pub-id>
      <fpage>599</fpage>
      <lpage>608</lpage>
    </element-citation>
  </ref>
  <ref id="ref-derveaux2010">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Derveaux</surname><given-names>Stefaan</given-names></name>
        <name><surname>Vandesompele</surname><given-names>Jo</given-names></name>
        <name><surname>Hellemans</surname><given-names>Jan</given-names></name>
      </person-group>
      <article-title>How to do successful gene expression analysis using real-time PCR</article-title>
      <source>Methods</source>
      <year iso-8601-date="2010-04-01">2010</year><month>04</month><day>01</day>
      <volume>50</volume>
      <issue>4</issue>
      <uri>https://www.sciencedirect.com/science/article/pii/S1046202309002461</uri>
      <pub-id pub-id-type="doi">10.1016/j.ymeth.2009.11.001</pub-id>
      <fpage>227</fpage>
      <lpage>230</lpage>
    </element-citation>
  </ref>
  <ref id="ref-weiß2018">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Weiß</surname><given-names>Frederik</given-names></name>
        <name><surname>Hammer</surname><given-names>Helen S.</given-names></name>
        <name><surname>Klein</surname><given-names>Kathrin</given-names></name>
        <name><surname>Planatscher</surname><given-names>Hannes</given-names></name>
        <name><surname>Zanger</surname><given-names>Ulrich M.</given-names></name>
        <name><surname>Norén</surname><given-names>Agneta</given-names></name>
        <name><surname>Wegler</surname><given-names>Christine</given-names></name>
        <name><surname>Artursson</surname><given-names>Per</given-names></name>
        <name><surname>Joos</surname><given-names>Thomas O.</given-names></name>
        <name><surname>Poetz</surname><given-names>Oliver</given-names></name>
      </person-group>
      <article-title>Direct Quantification of Cytochromes P450 and Drug Transporters-A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates</article-title>
      <source>Drug Metabolism and Disposition: The Biological Fate of Chemicals</source>
      <year iso-8601-date="2018-04">2018</year><month>04</month>
      <volume>46</volume>
      <issue>4</issue>
      <pub-id pub-id-type="doi">10.1124/dmd.117.078626</pub-id>
      <fpage>387</fpage>
      <lpage>396</lpage>
    </element-citation>
  </ref>
  <ref id="ref-savaryn2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Savaryn</surname><given-names>John P.</given-names></name>
        <name><surname>Liu</surname><given-names>Ning</given-names></name>
        <name><surname>Sun</surname><given-names>Jun</given-names></name>
        <name><surname>Ma</surname><given-names>Junli</given-names></name>
        <name><surname>Stresser</surname><given-names>David M.</given-names></name>
        <name><surname>Jenkins</surname><given-names>Gary</given-names></name>
      </person-group>
      <article-title>Enrichment-free High-throughput Liquid ChromatographyMultiple-Reaction Monitoring Quantification of Cytochrome P450 Proteins in Plated Human Hepatocytes Direct from 96-Well Plates Enables Routine Protein Induction Measurements</article-title>
      <source>Drug Metabolism and Disposition</source>
      <year iso-8601-date="2020-07-01">2020</year><month>07</month><day>01</day>
      <volume>48</volume>
      <issue>7</issue>
      <uri>https://dmd.aspetjournals.org/content/48/7/594</uri>
      <pub-id pub-id-type="doi">10.1124/dmd.120.090480</pub-id>
      <fpage>594</fpage>
      <lpage>602</lpage>
    </element-citation>
  </ref>
</ref-list>
<fn-group>
  <fn id="fn1">
    <label>1</label><p>Skip this?</p>
  </fn>
  <fn id="fn2">
    <label>2</label><p>Dog ikke fra nogle af disse 3 donorer, så måske
    bedre med: To assess the integrity of the RNA, we evaluated the RNA
    Integrity Number (RIN) for a subset of samples, which yielded values
    ranging from 7 to 9.8.
    To validate the RNA extraction method, we assessed the RNA Integrity
    Number (RIN) using the Agilent BioAnalyzer for a subset of samples
    not derived from the donors discussed in this article. These
    assessments yielded RIN values between 7 and 9.8, indicative of
    high-quality RNA.</p>
  </fn>
</fn-group>
</back>

<sub-article article-type="notebook" id="nb-4-nb-1">
<front-stub>
<title-group>
<article-title>Viability</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Svendsen</surname>
<given-names>Andreas</given-names>
</name>
<string-name>Andreas Svendsen</string-name>

</contrib>
</contrib-group>
</front-stub>

<body>
<sec id="viability-nb-1">
  <title>Viability</title>
  <sec id="setup-nb-1">
    <title>Setup</title>
    <sec id="nb-code-cell-1-nb-1" specific-use="notebook-code">
    <code language="r script">
library(data.table)
library(ggplot2)
library(patchwork)
library(here)
    </code>
    <sec id="nb-code-cell-1-output-0-nb-1" specific-use="notebook-output">
    <preformat>here() starts at C:/Users/alosvendsen/Documents/R/manuscript_one</preformat>
    </sec>
    </sec>
  </sec>
  <sec id="load-and-wrangle-data-nb-1">
    <title>Load and wrangle data</title>
    <sec id="nb-code-cell-2-nb-1" specific-use="notebook-code">
    <code language="r script">data &lt;- readRDS(here(&quot;notebooks/viability/data_processed/final_viability.rds&quot;))

# Convert 'day' to a factor
data[, day := as.factor(day)]

# Calculate the mean ATP for each donor on day 5
mean_day5 &lt;- data[day == 5, .(mean_ATP_day5 = mean(ATP)), by = .(donor)]

# Merge this back with the main data
data &lt;- merge(data, mean_day5, by = &quot;donor&quot;)

# Calculate the relative ATP
data[, relative_ATP := ATP / mean_ATP_day5]

# Calculate the mean relative ATP for each donor and day
mean_data &lt;- data[, .(mean_relative_ATP = mean(relative_ATP)), by = .(day, donor)]

# Calculate the overall mean across all donors for each day
overall_mean &lt;- mean_data[, .(overall_mean_ATP = mean(mean_relative_ATP)), by = day]
    </code>
    </sec>
  </sec>
  <sec id="plotting-nb-1">
    <title>Plotting</title>
    <sec id="overall-relative-viability-nb-1">
      <title>Overall relative viability</title>
      <sec id="nb-code-cell-3-nb-1" specific-use="notebook-code">
      <code language="r script"># Plotting
plot_relative_viability &lt;- 
ggplot() +
  geom_point(data = mean_data,
             mapping = aes(x = day, y = mean_relative_ATP, color = as.factor(donor))) +
  geom_point(data = overall_mean,
             mapping = aes(x = day, y = overall_mean_ATP),
             size = 5,
             alpha = 0.5) +
  labs(title = &quot;Mean ATP Relative to Day 5 Across Donors&quot;,
       x = &quot;Day&quot;,
       y = &quot;Mean Relative ATP&quot;) +
  scale_y_continuous(
    name = &quot;Relative viability&quot;,
    limits = c(0, NA)
  )
      </code>
      </sec>
      <sec id="cell-fig-viability-relative-overall-nb-1" specific-use="notebook-code">
      <code language="r script">plot_relative_viability
      </code>
      <fig id="fig-viability-relative-overall-nb-1">
        <caption><p>Note that the concentration of ATP of donor one on
        day 5 was to high. Data for this donor/day not
        trustworthy/viability to high. This yields a steep fall from day
        5 to 7</p></caption>
        <graphic mimetype="image" mime-subtype="png" xlink:href="Viability_files/figure-jats/fig-viability-relative-overall-1.png" />
      </fig>
      </sec>
    </sec>
    <sec id="overall-absolute-viability-nb-1">
      <title>Overall absolute viability</title>
      <sec id="nb-code-cell-4-nb-1" specific-use="notebook-code">
      <code language="r script">data &lt;- readRDS(here(&quot;notebooks/viability/data_processed/final_viability.rds&quot;))

mean_ATP &lt;- data[, mean(ATP, na.rm = TRUE), by = .(day, donor)]

plot_absolute_viability &lt;- 
ggplot() +
  geom_point(
    data = mean_ATP,
    mapping = aes(
      x = day,
      y = V1,
      color = as.factor(donor)
    )
  ) +
  labs(title = &quot;Absolute ATP content&quot;,
       x = &quot;Day&quot;,
       y = &quot;ATP content (pmol/spheroid&quot;) +
  scale_y_continuous(limits = c(0, NA))
      </code>
      </sec>
      <sec id="cell-fig-viability-absolute-overall-nb-1" specific-use="notebook-code">
      <code language="r script">#|
plot_absolute_viability
      </code>
      <fig id="fig-viability-absolute-overall-nb-1">
        <caption><p>Note that the concentration of ATP of donor one on
        day 5 was to high. Data for this donor/day not
        trustworthy/viability to high</p></caption>
        <graphic mimetype="image" mime-subtype="png" xlink:href="Viability_files/figure-jats/fig-viability-absolute-overall-1.png" />
      </fig>
      </sec>
    </sec>
    <sec id="plot-individual-donors-nb-1">
      <title>Plot individual donors</title>
      <sec id="nb-code-cell-5-nb-1" specific-use="notebook-code">
      <code language="r script"># Load data ---------------------------------------------------------------
data &lt;- readRDS(here(&quot;notebooks/viability/data_processed/final_viability.rds&quot;))


#### Donor 1 ####
donor_1 &lt;- data[donor == 1]

donor_1[, mean_ATP := mean(ATP), by = .(day)]

calibrator &lt;- donor_1[day == 5, mean_ATP][1]

donor_1[, relative_ATP := ATP / calibrator]

plot_donor_1 &lt;- 
ggplot(
  data = donor_1,
  aes(
    x=as.factor(day),
    y = relative_ATP
    )
  ) +
  geom_point() +
  stat_summary(fun = mean, color = &quot;red&quot;) +
  scale_y_continuous(name = &quot;ATP content relative to day 5&quot;, limits = c(0, 1.5))


#### Donor 2 ####
donor_2 &lt;- data[donor == 2]

donor_2[, mean_ATP := mean(ATP), by = .(day)]

calibrator &lt;- donor_2[day == 5, mean_ATP][1]

donor_2[, relative_ATP := ATP / calibrator]

plot_donor_2 &lt;- 
ggplot(
  data = donor_2,
  aes(
    x=as.factor(day),
    y = relative_ATP
  )
) +
  geom_point() +
  stat_summary(fun = mean, color = &quot;red&quot;) +
  scale_y_continuous(limits = c(0, 1.5))


#### Donor 3 ####
donor_3 &lt;- data[donor == 3]

donor_3[, mean_ATP := mean(ATP), by = .(day)]

calibrator &lt;- donor_3[day == 5, mean_ATP][1]

donor_3[, relative_ATP := ATP / calibrator]

plot_donor_3 &lt;- 
ggplot(
  data = donor_3,
  aes(
    x=as.factor(day),
    y = relative_ATP
  )
) +
  geom_point() +
  stat_summary(fun = mean, color = &quot;red&quot;)+
  scale_y_continuous(limits = c(0, 1.5))


plot_donor_relative_viability &lt;- 
  wrap_plots(list(plot_donor_1, plot_donor_2, plot_donor_3)) +
  plot_annotation(title = &quot;Individual donor viability relative to day 5&quot;)

# ggsave(plot = donor_relative_viability,
#        filename = here(&quot;notebooks/viability/output/donor_relative_viability.png&quot;))
      </code>
      </sec>
      <sec id="cell-fig-donor-viabilities-nb-1" specific-use="notebook-code">
      <code language="r script">
plot_donor_relative_viability
      </code>
      <fig id="fig-donor-viabilities-nb-1">
        <caption><p></p></caption>
        <graphic id="fig-donor-viabilities-nb-1" mimetype="image" mime-subtype="png" xlink:href="Viability_files/figure-jats/fig-donor-viabilities-1.png" />
      </fig>
      <sec id="cell-fig-donor-viabilities-output-0-nb-1" specific-use="notebook-output">
      <preformat>Warning: Removed 5 rows containing missing values (`geom_segment()`).</preformat>
      </sec>
      <sec id="cell-fig-donor-viabilities-output-1-nb-1" specific-use="notebook-output">
      <preformat>Warning: Removed 6 rows containing missing values (`geom_segment()`).</preformat>
      </sec>
      <sec id="cell-fig-donor-viabilities-output-2-nb-1" specific-use="notebook-output">
      <preformat>Warning: Removed 9 rows containing missing values (`geom_segment()`).</preformat>
      </sec>
      </sec>
      <sec id="nb-code-cell-6-nb-1" specific-use="notebook-code">
      <code language="r script">rmv &lt;- ls()[-grep(&quot;plot&quot;, ls())]
rm(list = rmv, rmv)
      </code>
      </sec>
    </sec>
  </sec>
</sec>
</body>



<back>
</back>


</sub-article>

</article>